Author Index
Volumes 31 and 32

A
Adachi K-I, 32:79
Adaikan G, 32:201
Ängeby-Möller K, 31:79
Agrawal DK, 32:73
Agrawal K, 32:4
Ahlenius S, 32:155
Alexander B, 32:117
Ali N, 32:187
Alongi V, 31:187
Arbabha B, 31:107
Armstrong JM, 31:31

B
Baker GB, 31:141, 31:177
Bambrick L, 32:129
Bansinath M, 31:107
Barozzi F, 31:187
Bast A, 31:149
Bellemin-Baurreau J, 31:31
Benedek G, 32:215
Benjamin IS, 32:117
Berge O-G, 31:79
Botrel MA, 32:63
Brain S, 32:41
Brennan BS, 32:139
Brodin E, 31:79
Browse DJ, 32:117
Brunden MN, 31:153
Brune K, 32:149
Bryer-Ash M, 31:215
Bungay PM, 32:169, 32:177

C
Caille D, 32:219
Camilleri JP, 32:53
Chand D, 31:95
Charieras T, 32:219
Chen S, 31:117
Cheung A, 31:215
Chevalier R, 32:63
Cingolani H, 32:7
Coceani F, 32:85
Colby HD, 32:1
Concordet D, 32:63
Coutts RT, 31:141, 31:177
Cozzolino R, 32:105
Cronau LH, 31:99

D
Dalsgaard C-J, 31:79
Daniels CK, 31:41
David T, 31:99
David Y, 31:99
Davies D, 32:139
Dedrick RL, 32:169, 32:177
Demiryürek AT, 32:35
Dhasmana KM, 31:59
Donnell D, 31:149

E
Eacho PI, 31:21
Edwards JD, 32:73
Elnatan A, 31:47
Erdmann W, 31:59
Erroi A, 31:187
Eschalier A, 32:197

F
Fankhauser C, 32:219
Fenstermacher JD, 32:169, 32:177
Ferro M, 31:187
Fialip J, 32:197
Floyd DM, 31:199
Foxworthy PS, 31:21
Furuhama K, 31:71, 31:161

G
Garg UC, 31:107
Geisslinger G, 32:149
Ghirardi O, 32:105
Giroud JP, 32:161
Giuliani A, 32:105
Godeau G, 32:161
Göthert M, 32:109
Goldstein RS, 31:11
Gordon T, 32:129
Greufe NP, 31:233
Guessous F, 32:161
Gupta OP, 31:95

H
Haak T, 32:63
Hammarström G, 31:79
Handler JA, 31:11
Hartman JC, 31:153
Hassoun A, 32:31
Hatanaka S, 31:161
Hayashi H, 31:1
Hayes E, 32:201
Healy DL, 32:49
Hempelmann E, 32:25
Hendriks MGC, 32:225
Herold H, 32:109
Heyward P, 32:49
Hicks PE, 31:31
Holt A, 31:141
Hornebeck W, 32:161
Horváth G, 32:215
Houston JB, 32:139
Hughes S, 32:41
Hullinger TG, 31:153
Huynh C, 32:161

I
Itoh T, 32:99

J
Jones RD, 31:233

K
Kagoshima M, 32:209

Kam KL, 32:225
Kamikawa Y, 31:207
Kandori H, 31:191
Kane KA, 32:35
Kao J, 31:99
Katagiri S, 32:209
Kawarabayashi K, 31:161
Komuro I, 32:19
Kondoh M, 31:161
Kossor DC, 31:11
Kovács M, 32:215
Krindel P, 32:169, 32:177
Kurosawa M, 31:135

L
Latinne D, 32:31
Legrand C, 32:63
Leurs R, 31:149
Lines L, 32:85
Little DK, 31:199
The Local Anesthetics for Neuralgia Study Group, 31:221
Longhurst PA, 31:53, 31:54, 31:55, 31:56, 31:57, 31:113, 31:114, 31:115, 31:116, 31:171, 31:172, 31:173, 31:174, 31:175, 32:61, 32:62, 32:123

M
Marques HM, 32:25
Martin SW, 32:139
Masuda Y, 32:99
Mathy M-J, 32:225
Mattiazzi A, 32:7
Mayer D, 32:93
McClure N, 32:49
McGregor PE, 32:73
Mercer-Connolly A, 32:85
Mestre C, 32:197
Meyer J, 32:161
Miller K, 32:93
Mitchelson F, 31:47
Miyamoto M, 31:71
Miyata H, 31:1
Mizuno T, 32:19
Moggi M, 31:187
Molin UD, 31:187
Monteith GR, 31:117
Mundiña-Weilenmann C, 32:7
Murai S, 32:99
Musser B, 31:41

N
Nagai R, 32:19
N'Guyen H, 32:161
Nickmilder MJ, 32:31

O
Ohkubo N, 32:99
Olszanski DA, 31:153

P
Pagani P, 31:187
Patlak CS, 32:169, 32:177
Paulson S, 32:93
Pélissier T, 32:197
Penz WP, 32:201
Pfaffendorf M, 32:225
Pijl AJ, 32:225
Poizot A, 31:31
Pugsley MK, 32:201

R
Rahwan RG, 32:59
Raval P, 32:125
Robertson DM, 32:49
Roch-Arveiller M, 32:161
Romano M, 31:187
Roufogalis BD, 31:117
Rovei V, 32:219
Rowland M, 32:139
Ruegg CE, 31:125

S
Sagara-Ishijima N, 31:71
Saito H, 32:99
Salmi P, 32:155
Salmona M, 31:187
Samuelsson J, 32:155
Sato K, 31:191
Sato S, 31:191
Sauernheimer C, 32:149
Schoenhard G, 32:93
Schött E, 31:79
Sharma N, 31:95
Shimada H, 32:209
Shiojima I, 32:19
Smith BL, 31:53
Sobotka JM, 32:59
Stanley TH, 31:99
Ståhle L, 31:167
Stevens AJ, 32:139
Su P, 31:177
Suzuki T, 32:209
Szelenyi I, 32:109
Szikszay M, 32:215

T
Takayama S, 31:71
Topley N, 32:53
Toutain PL, 32:63
Toyoda O, 32:85
Turndorf H, 31:107
Tymiak AA, 31:199

U
Uhlig S, 31:85

V
van der Wal AC, 32:225
van Zwieten PA, 32:225
Verhage L, 32:93
Vestal RE, 31:41
Vittone L, 32:7
Voss H-P, 31:149

W
Wadsworth RM, 32:35
Wainwright CL, 32:35
Walker MJA, 32:201
Wallemacq PE, 32:31
Wang Y, 32:85
Wilcox G, 32:197
Williams AS, 32:53
Williams BD, 32:53
Williams G, 32:41
Williams KM, 32:149
Williams T, 32:41
Wollin L, 31:85

Y
Yamaguchi F, 31:71
Yamazaki T, 32:19
Yazaki Y, 32:19

Z
Zavisca FG, 31:99
Zhang L, 31:41
Zhu YN, 31:59
Zucchi C, 31:187

Subject Index
Volumes 31 and 32

A

Abstracts, 31:53, 31:54, 31:55, 31:56, 31:57, 32:61, 32:62, 32:123
Acetaminophen
  gastric emptying measurement and, 31:161
  microdialysis and, 32:149
Acetic anhydride, derivatization with, 31:141
Acetylcholine receptors, characterization of, 32:129
Acquisition, computer-assisted two-way avoidance conditioning, 32:155
Adipose tissue, microdialysis experiments in, 31:167
Adrenal cortex, toxicity, 32:1
Adrenocortical toxicity, in vitro assessment of, 32:1
Agonists, gastrointestinal motility and, 31:59
Air pollutants, automated system for animal exposure to nitrogen dioxide, 31:187
Air-pouch inflammation, carrageenan in, 32:139
Airway smooth muscle function, neurogenic control of, 31:207
Algesia, automatic measurement of writhing and, 32:79
Alkaline secretion, measurement, 31:172
Alovudine, microdialysis experiments and, 31:167
Alpha$_2$-agonists, dexmedetomidine evaluation, 32:215
Analgesia, direct transcutaneous intrathecal injection in rats and, 32:197
Analgesic agents, automatic measurement of writhing and, 32:79
Anesthesia
  cardiovacular response with, 31:99
  etomidate and, 31:99
  nociceptive response with, 31:99
Angiotensin II
  cardiac hypertrophy and, 32:19
  nonequilibrium radioimmunoassay for, 32:93
Antagonists
  emesis induction with, 32:109
  gastrointestinal motility and, 31:59
Antiarrhythmic/antiischemic agents, programmed electrical stimulation for evaluation of, 31:31
Antiarthritic drugs, evaluation of slowly acting, 31:95
Anticancer agents, emetogenic potential of, 32:109
Antidepressants, derivatization with acetic anhydride and, 31:141
Antiemetogenic drugs, chemotherapy and, 32:109
Antipsychotics
  computer-assisted two-way avoidance conditioning and, 32:155
  derivatization with acetic anhydride and, 31:141
Aortic blood flow, transit-time ultrasonic volume flow meter, 31:153
Area-under-the-curve determination, 32:169, 32:177
Arthritis
  adjuvant-induced
    prostaglandin and tumor necrosis factor secretion with methotrexate in, 32:35
    quantitative evaluation of, 32:63
  experimental, Freund's Complete Adjuvant with, 32:63
Automatic detection of writhing, 32:79
Autonomic nervous system, anesthesia and, 31:99
Avoidance, conditioned, 32:155

B

Big endothelin, endothelin converting enzyme activity screening, 31:199
Binding assays, radioligand binding methods, 32:61
Biogenic amines, derivatization with acetic anhydride and, 31:141
Blood flow measurement, ^{133}Xenon and, 32:41
Blood pressure, anesthesia and, 31:99
Blood sampling, repeated, 31:161
Brain
  microdialysis experiments in, 31:167
  solid-phase radioimmunoassay for cyclic AMP, 31:41
Bronchoalveolar lavage fluid, automated system for animal exposure to nitrogen dioxide, 31:187
Bupivacaine, nerve irrigation system for, 31:221

C

$[Ca^{2+}]i$, fluorescence imaging of, 31:1
Calibration, transit-time ultrasonic volume flow meter, 31:153
Canine, quantitative electroencephalography for xenobiotic screening in, 31:233
Capillary filtration coefficient, perfused lung in determination of, 31:85

Cardiac hypertrophy, in vitro study of, 32:19
Carrageenan, pain-related behavior evaluation with, 31:79
Ca^{2+}-ATPase, hypertension and, 31:117
Ca^{2+} efflux, hypertension and, 31:117
Ca^{2+} influx, hypertension and, 31:117
Ca^{2+} pump, hypertension and, 31:117
Catecholamines, glucose insulin clamp studies in conscious rats and, 31:215
Catheterization
  for chronic intrathecal material administration, 31:113
  chronic vascular, 31:115
cDNA, qualitative/quantitative determination of mRNA, 32:125
Cell adhesion molecules, assessment of, 32:73
Cell proliferation, compound effect on, 31:171
Cerebellum, cyclic guanosine 3′5′-monophosphate (cGMP) analysis and, 31:107
CFU-E assay, hemotoxicity estimation in rats with, 31:71
CFU-GM assay, hemotoxicity estimation in rats with, 31:71
cGMP. *See* Cyclic guanosine 3′5′-monophosphate (cGMP)
Chemiluminescence, free-radical scavenging drugs and, 32:35
Circadian rhythm, left ventricular function and, 31:191
Clamp, glucose insulin, 31:215
Compounds, cell proliferation and, 31:171
Conditioned avoidance, computer-assisted two-way, 32:155
copy DNA. *See* cDNA
Coulometric detection in high-performance liquid chromatography, for norepinephrine and 3-methoxy-4-hydroxyphenylglycol, 32:99
Cross-flow membrane plasmapheresis, 32:177
Culture techniques, vascular smooth muscle studies and, 32:62
Cutaneous blood flow measurement, ^{133}Xenon and, 32:41
Cyclic AMP
  quantification of, 31:47
  solid-phase radioimmunoassay for, 31:41
Cyclic guanosine 3′5′-monophosphate (cGMP), nitric oxide and, 31:107
Cyclophosphamide, effects on bone marrow, 31:71
CYP3A isoenzymes, *N*-dealkylation, 31:177
CYP2D6, *N*-dealkylation, 31:177
Cytochrome P-450 isozymes, *N*-dealkylation, 31:177
Cytochrome P450IID1 (CYP2D1), radioligand binding assay for, 31:149
Cytochrome P450IID6 (CYP2D6), radioligand binding assay for, 31:149

D

Denervation, skeletal muscle, 32:129
Deoxyribonucleic acid. *See* DNA
Dephosphorylation, cellular function regulation and protein, 31:135
Dexmedetomidine, micturition and, 32:215
Diabetes mellitus, streptozotocin-induced, hypertension and, 32:225
Diastolic function, myocardial relaxation and, 32:7
DNA, qualitative/quantitative determination of mRNA, 32:125
Drug mechanism of action, gastrointestinal motility and, 31:59
Drug metabolism, cytochrome P-450 isozymes in *N*-dealkylation, 31:177
Duodenal wall motility, measurement, 31:172

E

Elastase, gingival inflammation model and, 32:161
Electrical stimulation, anesthesia and, 31:99
Electroencephalogram, quantitative, 31:233
Emesis, induction of, 32:109
Endothelial cells, vascular disease and, 32:73
Endothelin-1, vascular disease and, 32:73
Endothelin, perinatal pulmonary circulation and, 32:85
Endothelin converting enzyme, screening, 31:299
Endothelium, perinatal pulmonary circulation and, 32:85
ET-1 radioreceptor assay, 31:199
Evaluation model, antiarthritic drugs, 31:95
Experimental arthritis, Freund's Complete Adjuvant with, 32:63
Exposure system, nitrogen dioxide, 31:187
Exsanguination, vacuum-assisted, 31:114

F

Fluorescence microscopy, $[Ca^{2+}]i$, 31:1
Food, MAO inhibitor interaction with tyramine, 32:219
Formed elements, exchange between plasma and, 32:169, 32:177
Free radical scavengers, porcine leukocytes and, 32:35
Freund's Complete Adjuvant, experimental arthritis and, 32:63
Fura-2, $[Ca^{2+}]i$ imaging with, 31:1

G

G-proteins, characterization/identification of, 32:187
Gas chromatography, derivatization with acetic anhydride and, 31:141
Gastric emptying, measurement of, 31:161
Gastric ulcer, serosa-searing apparatus for producing, 32:209

Gastrointestinal system, drug effects on propulsion and motility in, 31:59
Gingival inflammation, model for assessment of, 32:161
Gloves, latex, xenopus laevis tadpoles and, 32:59
Granuloma, inflammation and, 32:139
Guanine nucleotide binding regulatory proteins, characterization/identification of, 32:187

H

[$_3$H]-mepyramine, sparteine/debrisoquine polymorphism and, 31:149
Harmaline, cyclic guanosine 3'5'-monophosphate (cGMP) analysis and, 31:107
Healing process, ulcers and, 32:209
Heart, solid-phase radioimmunoassay for cyclic AMP, 31:41
Heart rate, QaT and RR intervals and, 32:201
Hepatobiliary toxicity, xenobiotics and, 31:11
Hepatocarcinogenicity, peroxisome proliferation and, 31:21
Hepatocytes, peroxisome proliferation with cultured, 31:21
High molecular weight G-proteins, characterization/identification of, 32:187
High-performance liquid chromatography (HPLC) assay, cyclic AMP accumulation and, 31:47
HPLC, malaria pigment analysis from *plasmodium falciparum* and, 32:25
5-HT$_3$, emesis induction and, 32:109
Hyperplasia, intimal, 32:73
Hypertension
  spontaneously hypertensive rat, 31:117
  streptozotocin-induced diabetes mellitus and, 32:225
Hypoxia, liver perfusion and, 32:117

I

Ibuprofen, inflammation and, 32:139
Image analysis, of miles assay, 32:49
Implant, nerve irrigation system, 31:221
In vitro model, antiarrhythmic/antiischemic agent evaluation with programmed electrical stimulation, 31:31
In vivo analysis, microdialysis, 32:149
Indo-1, [Ca^{2+}]i imaging with, 31:1
Inflammation
  air-pouch, 32:139
  gingival, 32:161
  weight bearing for measurement of, 31:79
Inhibitory effects, of residues, 32:31
Inositol monophosphate, bioassay for neurokinin receptors and, 31:174
Intact cells, high-performance liquid chromatography (HPLC) assay and cyclic AMP accumulation, 31:47
Intracolonic pressure, measurement of, 31:59
Intragastric pressure, measurement of, 31:59
Intrathecal injection, direct transcutaneous, 32:197
Intrathecal material administration, chronic, 31:113
Introduodenal pressure, measurement of, 31:59
Ionomycin, free-radical scavenging activity and, 32:35
Ischemia-reperfusion, programmed electrical stimulation for, 31:31

K

Kidney models, in vitro, 31:125

L

Latex gloves, xenopus laevis tadpoles and, 32:59
Left ventricular pressure, telemetry for, 31:191
Leukocytes
  free radical scavengers and porcine, 32:35
  inflammation and, 32:139
Lipid accumulation, compounds and intracellular, 31:171
Liposome, prostaglandin and tumor necrosis factor secretion and, 32:35
Liver circulation, perfusion and vascular responses, 32:117
Local anesthetic, nerve irrigation system for, 31:221
Lung, perfused, setup for isolated, 31:85
Lung mechanics, perfused lung in assessment of, 31:85
Lusitropic drugs, cellular mechanisms of, 32:7
Lusitropism, myocardial relaxation and, 32:7
Lymphocytes, solid-phase radioimmunoassay for cyclic AMP, 31:41

M

Malaria pigment, *plasmodium falciparum* and, 32:25
MAO inhibitor, tyramine and, 32:219
MAP kinase, cardiac hypertrophy and, 32:19
Mass spectrometry, derivatization with acetic anhydride and, 31:141
Mechanical stress, cardiac hypertrophy and, 32:19
Membrane, Ca^{2+} efflux in hypertension, 31:117
Messenger ribonucleic acid. *See* mRNA
Metabolism
  blood sampling error estimation and, 32:169
  cross-flow membrane plasmapheresis and, 32:177
Methods, anesthetic depth study, 31:99
Methotrexate, prostaglandin and tumor necrosis factor secretion and, 32:35
3-Methoxy-4-hydroxyphenylglycol, high-performance liquid chromatography of, 32:99

Microdialysis
pharmacokinetics of analgesics and, 32:149
zidovudine and alovudine in, 31:167
Microvasculature, ^{133}Xenon and, 32:41
Micturition, dexmedetomidine effect on, 32:215
Miles assay, image analysis quantification of, 32:49
Mixed lymphocytes, inhibitory effects of residues on, 32:31
Monoarthritic rat, weight bearing as measure of pain in, 31:79
Monomeric G-proteins, characterization/identification of, 32:187
Mouse brain, norepinephrine and 3-methoxy-4-hydroxyphenylglycol detection in, 32:99
mRNA, qualitative/quantitative determination of, 32:125
Mucosal fluid transport, measurement, 31:172

N

Na+ channels, characterization of, 32:129
N-Dealkylation, metabolic, 31:177
Nephrotoxicant injury, 31:125
Nephrotoxicity, segment-specific, 31:125
Neuralgia polydimethylsiloxane (silicone), nerve irrigation system and, 31:221
Neurogenic control of airway smooth muscle function, 31:207
Neurokinin receptor bioassay, inositol monophosphate in, 31:174
Neurokinins, vascular disease and, 32:73
Neuromuscular plasticity, 32:129
Neurotoxins, neural regulation of membrane proteins in skeletal muscle and, 32:129
Neutrophils, vascular disease and, 32:73
Nitric oxide
characterization of, 32:123
cyclic guanosine 3′5′-monophosphate (cGMP) and, 31:107
perinatal pulmonary circulation and, 32:85
Nitrogen dioxide, automated system for animal exposure to, 31:187
Nociception, objective methods for quantitation of, 31:79
Nonequilibrium radioimmunoassay, for angiotensin II, 32:93
Nonmetabolized sugars, hepatobiliary function and, 31:11
Norepinephrine, high-performance liquid chromatography of, 32:99
Noxious stimulation, anesthesia and, 31:99

P

Pain
long-lasting, weight bearing as measure of, 31:79
nociceptive response with anesthesia and, 31:99
Papaya latex, antiarthritic drugs, slowly acting, and, 31:95
Perinatal pulmonary circulation, vasoactive agents and, 32:85
Periodontitis, gingival inflammation model, 32:161
Peristalsis, drug efficacy and, 31:116
Peroxisome proliferation, cultured hepatocytes and, 31:21
PGE_2. *See* Prostaglandin E_2
Pharmacokinetic/pharmacodynamic modelling, experimental inflammation with Freund's Complete Adjuvant, 32:63
Pharmacokinetics
acetaminophen, 32:149
cross-flow membrane plasmapheresis and, 32:177
whole-blood sampling and, 32:169
Phenylhydrazine, effects on bone marrow, 31:71
Phorbol ristate acetate, free-radical scavenging activity and, 32:35
Phosphorylation, cellular function regulation and protein, 31:135
Pigs, domestic, emesis induced in, 32:109
Plasma elements, exchange between formed and, 32:169, 32:177
Plasmapheresis, cross-flow membrane, 32:177
Plasmodium falciparum, malaria pigment analysis from, 32:25
Polymorphism, sparteine/debrisoquine, 31:139
Pressor effect, tyramine-induced, 32:219
Pressure, serosa-searing ulcer model and, 32:209
Programmed electrical stimulation, antiarrhythmic/antiischemic agent evaluation with, 31:31
Prostaglandin E_2, inflammation and, 32:139
Prostaglandin release, methotrexate and, 32:35
Protein, inflammation and, 32:139
Protein kinase, 31:135
Protein kinase cascade, cardiac hypertrophy and, 32:19
Protein phosphatase, 31:135

Q

QaT correction, 32:201

R

Rabbit
antiarrhythmic/antiischemic agent evaluation with programmed electrical stimulation, 31:31
blood flow measurement and ^{133}Xenon, 32:41
Radioimmunoassay
for angiotensin II, 32:93
for cyclic guanosine 3′5′-monophosphate (cGMP), 31:107

Radioligand binding assay
for cytochrome P450IId1 (CYP2D1), 31:149
practical guide/tips, 32:61
Ranking, Mann-Whitney's U test, 32:105
Rat
antiarthritic drugs, slowly acting, and inflammation, 31:95
computer-assisted two-way conditioned avoidance, 32:155
dexmedetomidine effect on micturition, 32:215
direct transcutaneous intrathecal injection, 32:197
gastric emptying measurement, 31:161
glucose insulin clamp studies, 31:215
hematotoxicity, 31:71
intragastric pressure measurement, 31:59
left ventricular pressure measurement with telemetry, 31:191
MAO inhibitor interaction with tyramine, 32:219
microdialysis and acetaminophen, 32:149
nociceptive response with anesthesia, 31:99
prostaglandin and tumor necrosis factor secretion with methotrexate, 32:35
radioligand binding assay for cytochrome P450IId1 (CYP2D1), 31:149
rat working heart, 32:225
serosa-searing ulcer model, 32:209
Recurrence, serosa-searing ulcer model and, 32:209
Relaxation parameters, myocardial, 32:7
Retention, computer-assisted two-way avoidance conditioning, 32:155
Ribonucleic acid. *See* RNA
RNA, qualitative/quantitative determination of mRNA, 32:125
Rodents, automated system for animal exposure to nitrogen dioxide, 31:187

S

S-nitroso-N-acetylpenicillamine (SNAP), cyclic guanosine 3'5'-monophosphate (cGMP) analysis and, 31:107
Sample storage artifact, 32:169
Sampling
continuous blood, 32:169, 32:177
continuous plasma, 32:169, 32:177
serial blood, 32:169, 32:177
Scales, nonparametric, 32:105
SDS PAGE, malaria pigment analysis from *plasmodium falciparum* and, 32:25
Segmental vascular resistance, perfused lung in determination of, 31:85
Serum, solid-phase radioimmunoassay for cyclic AMP, 31:41
Signal transduction, guanine nucleotide binding regulatory proteins and, 32:187
Single-channel activity, synaptic plastic membrane recording of, 31:173
Skeletal muscle, neural regulation of membrane proteins in, 32:129
Small animals, QaT and RR intervals in, 32:201
Smooth muscle
culture techniques and vascular, 32:62
guanine nucleotide binding regulatory proteins in, 32:187
neurogenic control of airway, 31:207
SNAP. *See* S-nitroso-N-acetylpenicillamine (SNAP)
Solid-phase extraction residues, inhibitory effects of, 32:31
Solid-phase radioimmunoassay, cyclic AMP, 31:41
Sparteine/debrisoquine polymorphism, 31:139
Statistical methods, descriptive index, 32:105
Storage, sample storage artifact, 32:169
Streptozotocin-induced diabetes mellitus, hypertension and, 32:225
Sugars, nonmetabolized, 31:11
Synaptic plastic membrane, recording of single-channel activity from, 31:173

T

Tachyphylaxis, implantable nerve irrigation system and, 31:221
Tadpoles, xenopus laevis, latex gloves and, 32:59
TCV-116, cardiac hypertrophy and, 32:19
Telemetry, left ventricular pressure with, 31:191
Toxicological screen, 31:233
Transforming growth factor β, bioassay for, 31:175
Transit time, ultrasound blood flow metering system, 31:153
Tumor necrosis factor secretion, methotrexate and, 32:35
Tyramine, MAO inhibitor interaction with, 32:219

U

Ulcer, gastric, serosa-searing apparatus for producing, 32:209
Ultrasound
dexmedetomidine effect on micturition and, 32:215
transit-time ultrasonic volume flow meter, 31:153
Ureteral peristaltic pressure, drug efficacy and, 31:116
Urinary bladder, dexmedetomidine effect on micturition, 32:215
Urine, solid-phase radioimmunoassay for cyclic AMP, 31:41
UV-Vis spectra, malaria pigment analysis from *plasmodium falciparum* and, 32:25

V

Vacuum-assisted exsanguination, 31:114
Vagal and atrial stimulation, 32:201
Validation, experimental inflammation with Freund's Complete Adjuvant, 32:63
Vascular catheterization, chronic, 31:115
Vascular permeability, Miles assay for, 32:49
Vascular responses, liver perfusion and, 32:117

W

Weight bearing, pain measurement with, 31:79
Wheatstone bridge, automatic detection of writhing and, 32:79
Whole tissues, high-performance liquid chromatography (HPLC) assay and cyclic AMP accumulation, 31:47

X

Xenobiotics, hepatobiliary toxicity and, 31:11
^{133}Xenon, skin blood flow measurement and, 32:41
Xenopus laevis tadpoles, latex gloves and, 32:59

Z

Zidovudine, microdialysis experiments and, 31:167